Sequencing New Agents in Prostate Cancer

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses sequencing agents in prostate cancer.

Clinical Pearls

James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses sequencing agents in prostate cancer.

  • The FDA has approved 5 agents in the last 5 years, each of which extend survival by 2-5 months in patients with prostate cancer
  • There remains a need to determine the appropriate sequencing of these agents
  • Research is being conducted to develop a biomarker of response to hormonal therapy
  • Research is being conducted in mouse models to reach an answer quickly, rather than wait for a clinical trial